Company intelligence / Profile preview
DexTech Medical AB
Uppsala, Swedendextechmedical.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OsteoDex, the lead candidate for castration-resistant prostate cancer with bone metastases, has completed a successful Phase 2 study showing high tolerability, mild side effects, and treatment effect in patients who failed existing drugs. The company aims to out-license its drug candidates after completion of Phase 2 studies.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeModified carbohydrate molecule-based drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on DexTech Medical AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DexTech Medical AB.